发明名称 Antibody fusion proteins with a modified FcRn binding site
摘要 Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.
申请公布号 US8907066(B2) 申请公布日期 2014.12.09
申请号 US201012763662 申请日期 2010.04.20
申请人 Merck Patent GmbH 发明人 Lo Kin-Ming;Stein Pascal A.
分类号 C12P21/08;C07K16/46;C07K14/565;A61K38/00;A61K38/21;A61K39/00;C07K16/00 主分类号 C12P21/08
代理机构 Goodwin Procter LLP 代理人 Goodwin Procter LLP
主权项 1. A protein comprising two polypeptide chains, wherein the first polypeptide chain comprises native mature human interferon-β and at least a portion of an IgG constant region, the second polypeptide chain comprises at least a portion of an IgG constant region, and one of the polypeptide chains comprises a substitution corresponding to position 435 in the IgG FcRn binding site, wherein the substitution is H435A.
地址 Darmstadt DE